Most patients who receive a diagnosis of non-small cell lung
cancer (NSCLC) have advanced disease and are not curable with surgery.
Developments in the technology of radiation therapy (RT) have
contributed to the broad utility of this treatment modality in both a
curative and palliative capacity. Many patients at all stages,
including those who are medically inoperable, may benefit from RT.
Locally advanced NSCLC is treated commonly with combined modality
therapy. Novel RT administration schedules and chemotherapy regimens
for combined modality therapy are essential for improving the
management of NSCLC. Additional benefits can be foreseen as new
strategies for patient selection emerge.